Labcorp Holdings Inc. (LH) Stock Analysis
Healthcare · Diagnostics & Research
Wait for pullback to $250.61. At $261.90 the A.R:R is 1.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $250.61 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Thin upside margin: 7.1%.
Labcorp Holdings is a global laboratory services company with nearly 71,000 employees serving approximately 100 countries, performing 750M+ tests annually in 2025. Revenue is from diagnostic testing (Dx) billed to third-party payors and biopharma laboratory services (BLS)... Read more
Wait for pullback to $250.61. At $261.90 the A.R:R is 1.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $250.61 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Thin upside margin: 7.1%. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Earnings in 0 days. Wait until post-earnings. Score 5.0/10, moderate confidence.
Passes 3/6 gates (clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicnon-U.S. operations10-K Item 1A: 'BLS derives a significant portion of its revenues from non-U.S. operations'
Material Events(8-K, last 90d)
- 2026-02-09Item 5.02LOWJohn H. Sampson, M.D., Ph.D. (vice chancellor, University of Colorado Anschutz) appointed to Board effective February 9, 2026; assigned to Quality and Compliance Committee. Standard director compensation.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $250.61. At $261.90 the A.R:R is 1.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $250.61 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Thin upside margin: 7.1%. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Earnings in 0 days. Wait until post-earnings. Target $279.05 (+6.5%), stop $235.75 (−11.1%), Setup A.R:R 2.0:1. Score 5.0/10, moderate confidence.
Take-profit target: $279.05 (+9.0% upside). Target $279.05 (+6.5%), stop $235.75 (−11.1%), Setup A.R:R 2.0:1. Stop-loss: $235.75.
Thin upside margin: 7.1%.
Labcorp Holdings Inc. trades at a P/E of 24.6 (forward 13.3). TrendMatrix value score: 6.8/10. Verdict: Buy (Wait for Entry).
29 analysts cover LH with a consensus score of 4.1/5. Average price target: $310.
What does Labcorp Holdings Inc. do?Labcorp Holdings is a global laboratory services company with nearly 71,000 employees serving approximately 100...
Labcorp Holdings is a global laboratory services company with nearly 71,000 employees serving approximately 100 countries, performing 750M+ tests annually in 2025. Revenue is from diagnostic testing (Dx) billed to third-party payors and biopharma laboratory services (BLS) supporting pharmaceutical R&D. Supported more than 85%% of FDA-approved new drugs in 2025.